Dermatological side effects in rheumatological patients taking anti TNF-α treatment Article Swipe
Serpil Tuna
,
Sevil Alan
,
Ülkü Uçar
,
Mehmet Arman
·
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.5505/abantmedj.2016.79058
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.5505/abantmedj.2016.79058
INTRODUCTION: In this study, we aimed to investigate dermatological side effects DSE seen in patients with rheumatic diseases taking TNF-α blocker. METHODS: A total number of 103 patients with chronic inflammatory rheumatic diseases on TNF-α blocker treatment were included into the study. All cutaneous leisons in patients were recorded as before and after TNF-α blocker treatment. TNF-α blockers-related DSE were grouped as infectious and non-infectious. The demographic and clinical characteristics of patients with DSE examined. In addition, demographic and clinical characteristics of the patients with infectious and non-infectious DSE were compared.RESULTS: 103 patients 40 female between the age of 18-74 were included into the study. Totally 63 cutaneous leisons occured during TNF-α blocker treatment were determined in 50 % 48.54 patients. 25 onychomycosis, 7 psoriasis, 1 diskoid lupus eritematozus, 1 basal cell carcinoma, 1 palmoplantar pustulosis, 28 other cutaneous lesions. 36 72% of patients with DSE had infectious skin lesions. 14 38% of patients with DSE had non-infectious skin. DSE were significantly higher in patients receiving concomitant methotrexate MTX . İnfectious DSE were significantly higher than non infectious DSE in patients receiving concomitant MTX. There was no relationship between DSE with the type of TNF-α blocker and rheumatic diseases.DISCUSSION AND CONCLUSION: As a result, DSE ranging from onychomycosis to malignancies can be seen during be seen during TNF-α blocker therapy. Monitoring for DSE of the patients receiving TNF-α blocker treatment is important for early diagnosis and treatment.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.5505/abantmedj.2016.79058
- OA Status
- diamond
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4255894841
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4255894841Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.5505/abantmedj.2016.79058Digital Object Identifier
- Title
-
Dermatological side effects in rheumatological patients taking anti TNF-α treatmentWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2016Year of publication
- Publication date
-
2016-01-01Full publication date if available
- Authors
-
Serpil Tuna, Sevil Alan, Ülkü Uçar, Mehmet ArmanList of authors in order
- Landing page
-
https://doi.org/10.5505/abantmedj.2016.79058Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.5505/abantmedj.2016.79058Direct OA link when available
- Concepts
-
Medicine, Dermatology, Tumor necrosis factor alpha, Side effect (computer science), Traditional medicine, Internal medicine, Computer science, Programming languageTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4255894841 |
|---|---|
| doi | https://doi.org/10.5505/abantmedj.2016.79058 |
| ids.doi | https://doi.org/10.5505/abantmedj.2016.79058 |
| ids.openalex | https://openalex.org/W4255894841 |
| fwci | 0.0 |
| type | article |
| title | Dermatological side effects in rheumatological patients taking anti TNF-α treatment |
| biblio.issue | 1 |
| biblio.volume | 5 |
| biblio.last_page | 7 |
| biblio.first_page | 1 |
| topics[0].id | https://openalex.org/T11730 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9955999851226807 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2734 |
| topics[0].subfield.display_name | Pathology and Forensic Medicine |
| topics[0].display_name | Autoimmune Bullous Skin Diseases |
| topics[1].id | https://openalex.org/T12438 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9939000010490417 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2745 |
| topics[1].subfield.display_name | Rheumatology |
| topics[1].display_name | Urticaria and Related Conditions |
| topics[2].id | https://openalex.org/T11330 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9884999990463257 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2734 |
| topics[2].subfield.display_name | Pathology and Forensic Medicine |
| topics[2].display_name | Systemic Sclerosis and Related Diseases |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9914134740829468 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C16005928 |
| concepts[1].level | 1 |
| concepts[1].score | 0.5741686224937439 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q171171 |
| concepts[1].display_name | Dermatology |
| concepts[2].id | https://openalex.org/C17991360 |
| concepts[2].level | 2 |
| concepts[2].score | 0.5547095537185669 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q21173843 |
| concepts[2].display_name | Tumor necrosis factor alpha |
| concepts[3].id | https://openalex.org/C3454156 |
| concepts[3].level | 2 |
| concepts[3].score | 0.523685097694397 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1144241 |
| concepts[3].display_name | Side effect (computer science) |
| concepts[4].id | https://openalex.org/C556039675 |
| concepts[4].level | 1 |
| concepts[4].score | 0.32673218846321106 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q771035 |
| concepts[4].display_name | Traditional medicine |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.2931797504425049 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C41008148 |
| concepts[6].level | 0 |
| concepts[6].score | 0.0 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[6].display_name | Computer science |
| concepts[7].id | https://openalex.org/C199360897 |
| concepts[7].level | 1 |
| concepts[7].score | 0.0 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q9143 |
| concepts[7].display_name | Programming language |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9914134740829468 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/dermatology |
| keywords[1].score | 0.5741686224937439 |
| keywords[1].display_name | Dermatology |
| keywords[2].id | https://openalex.org/keywords/tumor-necrosis-factor-alpha |
| keywords[2].score | 0.5547095537185669 |
| keywords[2].display_name | Tumor necrosis factor alpha |
| keywords[3].id | https://openalex.org/keywords/side-effect |
| keywords[3].score | 0.523685097694397 |
| keywords[3].display_name | Side effect (computer science) |
| keywords[4].id | https://openalex.org/keywords/traditional-medicine |
| keywords[4].score | 0.32673218846321106 |
| keywords[4].display_name | Traditional medicine |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.2931797504425049 |
| keywords[5].display_name | Internal medicine |
| language | en |
| locations[0].id | doi:10.5505/abantmedj.2016.79058 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210234028 |
| locations[0].source.issn | 2147-1800 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2147-1800 |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Abant Medical Journal |
| locations[0].source.host_organization | |
| locations[0].source.host_organization_name | |
| locations[0].source.host_organization_lineage | |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Abant Medical Journal |
| locations[0].landing_page_url | https://doi.org/10.5505/abantmedj.2016.79058 |
| locations[1].id | pmh:oai:dergipark.org.tr:article/766522 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306499999 |
| locations[1].source.issn | |
| locations[1].source.type | journal |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | Abant Tıp Dergisi |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].source.host_organization_lineage | |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | info:eu-repo/semantics/article |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Abant Tıp Dergisi |
| locations[1].landing_page_url | https://dergipark.org.tr/tr/pub/abantmedj/issue/55924/766522 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5031186814 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-8717-1141 |
| authorships[0].author.display_name | Serpil Tuna |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Serpil Tuna |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5032877392 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-4233-0812 |
| authorships[1].author.display_name | Sevil Alan |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Sevil Alan |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5007015911 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-4838-1650 |
| authorships[2].author.display_name | Ülkü Uçar |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Ülkü Uçar |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5003953546 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-3433-8101 |
| authorships[3].author.display_name | Mehmet Arman |
| authorships[3].author_position | last |
| authorships[3].raw_author_name | Mehmet İhsan Arman |
| authorships[3].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.5505/abantmedj.2016.79058 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2022-05-12T00:00:00 |
| display_name | Dermatological side effects in rheumatological patients taking anti TNF-α treatment |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11730 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9955999851226807 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2734 |
| primary_topic.subfield.display_name | Pathology and Forensic Medicine |
| primary_topic.display_name | Autoimmune Bullous Skin Diseases |
| related_works | https://openalex.org/W2899084033, https://openalex.org/W2748952813, https://openalex.org/W3031052312, https://openalex.org/W3032375762, https://openalex.org/W1995515455, https://openalex.org/W2080531066, https://openalex.org/W3108674512, https://openalex.org/W1506200166, https://openalex.org/W2048182022, https://openalex.org/W2604872355 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.5505/abantmedj.2016.79058 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210234028 |
| best_oa_location.source.issn | 2147-1800 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2147-1800 |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Abant Medical Journal |
| best_oa_location.source.host_organization | |
| best_oa_location.source.host_organization_name | |
| best_oa_location.source.host_organization_lineage | |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Abant Medical Journal |
| best_oa_location.landing_page_url | https://doi.org/10.5505/abantmedj.2016.79058 |
| primary_location.id | doi:10.5505/abantmedj.2016.79058 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210234028 |
| primary_location.source.issn | 2147-1800 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2147-1800 |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Abant Medical Journal |
| primary_location.source.host_organization | |
| primary_location.source.host_organization_name | |
| primary_location.source.host_organization_lineage | |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Abant Medical Journal |
| primary_location.landing_page_url | https://doi.org/10.5505/abantmedj.2016.79058 |
| publication_date | 2016-01-01 |
| publication_year | 2016 |
| referenced_works_count | 0 |
| abstract_inverted_index.% | 118 |
| abstract_inverted_index.. | 169 |
| abstract_inverted_index.1 | 125, 129, 133 |
| abstract_inverted_index.7 | 123 |
| abstract_inverted_index.A | 22 |
| abstract_inverted_index.a | 202 |
| abstract_inverted_index.14 | 150 |
| abstract_inverted_index.25 | 121 |
| abstract_inverted_index.28 | 136 |
| abstract_inverted_index.36 | 140 |
| abstract_inverted_index.40 | 93 |
| abstract_inverted_index.50 | 117 |
| abstract_inverted_index.63 | 106 |
| abstract_inverted_index.As | 201 |
| abstract_inverted_index.In | 1, 75 |
| abstract_inverted_index.as | 49, 61 |
| abstract_inverted_index.be | 211, 214 |
| abstract_inverted_index.in | 13, 45, 116, 163, 179 |
| abstract_inverted_index.is | 230 |
| abstract_inverted_index.no | 186 |
| abstract_inverted_index.of | 25, 70, 81, 98, 142, 152, 193, 223 |
| abstract_inverted_index.on | 33 |
| abstract_inverted_index.to | 6, 208 |
| abstract_inverted_index.we | 4 |
| abstract_inverted_index.103 | 26, 91 |
| abstract_inverted_index.38% | 151 |
| abstract_inverted_index.72% | 141 |
| abstract_inverted_index.AND | 199 |
| abstract_inverted_index.All | 42 |
| abstract_inverted_index.DSE | 11, 58, 73, 88, 145, 155, 159, 171, 178, 189, 204, 222 |
| abstract_inverted_index.MTX | 168 |
| abstract_inverted_index.The | 65 |
| abstract_inverted_index.age | 97 |
| abstract_inverted_index.and | 51, 63, 67, 78, 86, 196, 235 |
| abstract_inverted_index.can | 210 |
| abstract_inverted_index.for | 221, 232 |
| abstract_inverted_index.had | 146, 156 |
| abstract_inverted_index.non | 176 |
| abstract_inverted_index.the | 40, 82, 96, 103, 191, 224 |
| abstract_inverted_index.was | 185 |
| abstract_inverted_index.MTX. | 183 |
| abstract_inverted_index.cell | 131 |
| abstract_inverted_index.from | 206 |
| abstract_inverted_index.into | 39, 102 |
| abstract_inverted_index.seen | 12, 212, 215 |
| abstract_inverted_index.side | 9 |
| abstract_inverted_index.skin | 148 |
| abstract_inverted_index.than | 175 |
| abstract_inverted_index.this | 2 |
| abstract_inverted_index.type | 192 |
| abstract_inverted_index.were | 37, 47, 59, 89, 100, 114, 160, 172 |
| abstract_inverted_index.with | 15, 28, 72, 84, 144, 154, 190 |
| abstract_inverted_index.18-74 | 99 |
| abstract_inverted_index.48.54 | 119 |
| abstract_inverted_index.There | 184 |
| abstract_inverted_index.after | 52 |
| abstract_inverted_index.aimed | 5 |
| abstract_inverted_index.basal | 130 |
| abstract_inverted_index.early | 233 |
| abstract_inverted_index.lupus | 127 |
| abstract_inverted_index.other | 137 |
| abstract_inverted_index.skin. | 158 |
| abstract_inverted_index.total | 23 |
| abstract_inverted_index.TNF-α | 19, 34, 53, 56, 111, 194, 217, 227 |
| abstract_inverted_index.before | 50 |
| abstract_inverted_index.during | 110, 213, 216 |
| abstract_inverted_index.female | 94 |
| abstract_inverted_index.higher | 162, 174 |
| abstract_inverted_index.number | 24 |
| abstract_inverted_index.study, | 3 |
| abstract_inverted_index.study. | 41, 104 |
| abstract_inverted_index.taking | 18 |
| abstract_inverted_index.Totally | 105 |
| abstract_inverted_index.between | 95, 188 |
| abstract_inverted_index.blocker | 35, 54, 112, 195, 218, 228 |
| abstract_inverted_index.chronic | 29 |
| abstract_inverted_index.diskoid | 126 |
| abstract_inverted_index.effects | 10 |
| abstract_inverted_index.grouped | 60 |
| abstract_inverted_index.leisons | 44, 108 |
| abstract_inverted_index.occured | 109 |
| abstract_inverted_index.ranging | 205 |
| abstract_inverted_index.result, | 203 |
| abstract_inverted_index.METHODS: | 21 |
| abstract_inverted_index.blocker. | 20 |
| abstract_inverted_index.clinical | 68, 79 |
| abstract_inverted_index.diseases | 17, 32 |
| abstract_inverted_index.included | 38, 101 |
| abstract_inverted_index.lesions. | 139, 149 |
| abstract_inverted_index.patients | 14, 27, 46, 71, 83, 92, 143, 153, 164, 180, 225 |
| abstract_inverted_index.recorded | 48 |
| abstract_inverted_index.therapy. | 219 |
| abstract_inverted_index.addition, | 76 |
| abstract_inverted_index.cutaneous | 43, 107, 138 |
| abstract_inverted_index.diagnosis | 234 |
| abstract_inverted_index.examined. | 74 |
| abstract_inverted_index.important | 231 |
| abstract_inverted_index.patients. | 120 |
| abstract_inverted_index.receiving | 165, 181, 226 |
| abstract_inverted_index.rheumatic | 16, 31, 197 |
| abstract_inverted_index.treatment | 36, 113, 229 |
| abstract_inverted_index.Monitoring | 220 |
| abstract_inverted_index.carcinoma, | 132 |
| abstract_inverted_index.determined | 115 |
| abstract_inverted_index.infectious | 62, 85, 147, 177 |
| abstract_inverted_index.psoriasis, | 124 |
| abstract_inverted_index.treatment. | 55, 236 |
| abstract_inverted_index.CONCLUSION: | 200 |
| abstract_inverted_index.concomitant | 166, 182 |
| abstract_inverted_index.demographic | 66, 77 |
| abstract_inverted_index.investigate | 7 |
| abstract_inverted_index.pustulosis, | 135 |
| abstract_inverted_index.İnfectious | 170 |
| abstract_inverted_index.inflammatory | 30 |
| abstract_inverted_index.malignancies | 209 |
| abstract_inverted_index.methotrexate | 167 |
| abstract_inverted_index.palmoplantar | 134 |
| abstract_inverted_index.relationship | 187 |
| abstract_inverted_index.INTRODUCTION: | 0 |
| abstract_inverted_index.eritematozus, | 128 |
| abstract_inverted_index.onychomycosis | 207 |
| abstract_inverted_index.significantly | 161, 173 |
| abstract_inverted_index.dermatological | 8 |
| abstract_inverted_index.non-infectious | 87, 157 |
| abstract_inverted_index.onychomycosis, | 122 |
| abstract_inverted_index.characteristics | 69, 80 |
| abstract_inverted_index.non-infectious. | 64 |
| abstract_inverted_index.blockers-related | 57 |
| abstract_inverted_index.compared.RESULTS: | 90 |
| abstract_inverted_index.diseases.DISCUSSION | 198 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 4 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7900000214576721 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.33970276 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |